| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| IL-22 R alpha 1 | Cynomolgus IL-22 R alpha 1 Protein, His Tag (MALS & SPR verified) |  Cynomolgus | HEK293 |  | MALSSDS-PAGE | $390.00 100ug |   | ||
| IL-22 R alpha 1 | Human IL-22 R alpha 1 Superstable Mutant Protein, Fc Tag (MALS verified) |  Human | HEK293 |  | MALSSDS-PAGE | $430.00 100ug | | ||
| IL-22 R alpha 1 | Human IL-22 R alpha 1 Superstable Mutant Protein, His Tag (MALS & SPR verified) | Human | HEK293 |  | MALSSDS-PAGE | $390.00 100ug | | ||
| IL-22 R alpha 1 | Avitag IL1-H82E5 | Biotinylated Human IL-22 R alpha 1 Superstable Mutant Protein, His,Avitag™ (HPLC verified) | Human | HEK293 |  | HPLCSDS-PAGE | $360.00 25ug | | |
| IL-22 R alpha 1 | Mouse IL-22 R alpha 1 Protein, His Tag (MALS & SPR verified) |  Mouse | HEK293 |  | MALSSDS-PAGE | $390.00 100ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Efmarodocokin alfa | RO-7021610; UTTR-1147A; RG-7880 | Phase 2 Clinical | Genentech Inc | Colitis, Ulcerative; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Diabetic Foot; Graft vs Host Disease | Details |
| Temtokibart | ARGX-112; LEO-138559; LP-0145 | Phase 2 Clinical | Argenx Se, Leo Pharma Inc | Dermatitis, Atopic | Details |
| CK-0045 | CK-0045 | Phase 2 Clinical | Cytoki Pharma ApS | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| Eflepedocokin alfa | F-652 | Phase 2 Clinical | Evive Biotech Ltd | Acute-On-Chronic Liver Failure; Coronavirus Disease 2019 (COVID-19); Enteritis; Enterocolitis, Necrotizing; Graft vs Host Disease; Hepatitis, Alcoholic; Pancreatitis | Details |
| ABBV-022 | ABBV-022 | Phase 1 Clinical | Abbvie Inc | Colitis, Ulcerative | Details |
